TY - JOUR
T1 - Treatment of metastatic breast cancer
AU - Gradishar, William J.
PY - 2014/5/1
Y1 - 2014/5/1
N2 - Many newer agents in combination are being studied in the frontline treatment of women with HER2-positive metastatic breast cancer (MBC), but the story in the endocrine arena is more about the wise use of new strategies to overcome endocrine resistance, because no new antihormonal agents have been approved in the past decade. During his presentation at the NCCN 19th Annual Conference, Dr. William Gradishar explored what's new in the treatment of MBC, focusing primarily on enhancing the effect of endocrine therapy to overcome resistance with newer targeted agents such as everolimus, reevaluating the role of rebiopsy on disease progression and measuring circulating tumor cells as a surrogate of response to treatment, and reviewing the effective treatment regimens for HER2-positive disease.
AB - Many newer agents in combination are being studied in the frontline treatment of women with HER2-positive metastatic breast cancer (MBC), but the story in the endocrine arena is more about the wise use of new strategies to overcome endocrine resistance, because no new antihormonal agents have been approved in the past decade. During his presentation at the NCCN 19th Annual Conference, Dr. William Gradishar explored what's new in the treatment of MBC, focusing primarily on enhancing the effect of endocrine therapy to overcome resistance with newer targeted agents such as everolimus, reevaluating the role of rebiopsy on disease progression and measuring circulating tumor cells as a surrogate of response to treatment, and reviewing the effective treatment regimens for HER2-positive disease.
UR - http://www.scopus.com/inward/record.url?scp=84902489300&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902489300&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2014.0184
DO - 10.6004/jnccn.2014.0184
M3 - Article
C2 - 24853211
AN - SCOPUS:84902489300
SN - 1540-1405
VL - 12
SP - 759
EP - 761
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 5 SUPPL.
ER -
